ZA8 Stock Chart & Stats
€22.56
-€0.50(-3.57%)
At close: 4:00 PM EST
€22.56
-€0.50(-3.57%)
Day’s Range― - ―
52-Week Range€10.00 - €25.00
Previous CloseN/A
Volume0.00
Average Volume (3M)21.00
Market Cap
€1.74B
Enterprise Value€1.48B
Total Cash (Recent Filing)€364.73M
Total Debt (Recent Filing)€17.04M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Jul 30, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.37
Shares Outstanding73,023,060
10 Day Avg. Volume0
30 Day Avg. Volume21
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.39
Price to Sales (P/S)18.72
P/FCF Ratio-57.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€33.07Price Target Upside46.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.34
Revenue Forecast (FY)€283.60M
Bulls Say, Bears Say
Bulls Say
Improved Cash Runway And Milestone VisibilityA materially stronger cash balance plus management’s cited $440M of anticipated regulatory milestones extends the firm’s runway through 2028 under base assumptions. This materially reduces near-term financing risk, allows sustained R&D and dealmaking capacity, and supports multi-year execution of clinical programs.
Revenue Diversification Via Theravance Acquisition And YUPELRI RoyaltiesThe Theravance transaction structurally shifts Zymeworks toward recurring, royalty-driven cash flows (YUPELRI) and identifiable intangible assets, reducing pure milestone dependency. Steady product royalties can fund R&D and lower funding volatility, improving long-term cash generation and strategic flexibility.
Encouraging Clinical Signal For ZW191 (internal Asset)Compelling early efficacy and disease‑control signals for ZW191 increase the probability of internal value creation versus pure reliance on partner milestones. Durable clinical activity in platinum‑resistant gynecologic tumors supports potential partnering or commercialization strategies that can deliver recurring revenues long term.
Bears Say
Persistent Negative Operating Cash Flow And Deep Cash BurnSustained negative operating and free cash flow implies ongoing funding needs absent material revenue inflection. Over multiple years this pressure can force dilutive financing, constrain R&D choices, or necessitate asset sales/partnerships, making long-term program execution contingent on external financing or milestone realization.
Sharp Revenue Decline And Dependence On Partner MilestonesLarge YoY revenue volatility driven by lumpy, partner‑dependent milestones undermines predictability of cash flow. Structural reliance on partner approvals and royalty timing elevates financing and execution risk, since near‑term operations hinge on events outside Zymeworks’ direct control.
Pipeline Timing And Execution Risk (delays And Preclinical Programs)Material timeline slippages and extensive IND‑enabling requirements for preclinical ADCs mean value realization could be pushed out and costs increased. Protracted development increases funding needs and the chance that assets will require partners for scaling, raising long‑term execution and commercialization risk.
Zymeworks News
ZA8 FAQ
What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was €10.00 and its highest was €25.00 in the past 12 months.
What is Zymeworks’s market cap?
Zymeworks’s market cap is €1.74B.
When is Zymeworks’s upcoming earnings report date?
Zymeworks’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Zymeworks’s earnings last quarter?
Zymeworks released its earnings results on May 07, 2026. The company reported -€0.515 earnings per share for the quarter, missing the consensus estimate of -€0.259 by -€0.256.
Is Zymeworks overvalued?
According to Wall Street analysts Zymeworks’s price is currently Undervalued.
Does Zymeworks pay dividends?
Zymeworks does not currently pay dividends.
What is Zymeworks’s EPS estimate?
Zymeworks’s EPS estimate is -0.33.
How many shares outstanding does Zymeworks have?
Zymeworks has 73,023,060 shares outstanding.
What happened to Zymeworks’s price movement after its last earnings report?
Zymeworks reported an EPS of -€0.515 in its last earnings report, missing expectations of -€0.259. Following the earnings report the stock price went down -8.257%.
Which hedge fund is a major shareholder of Zymeworks?
Currently, no hedge funds are holding shares in DE:ZA8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€33.07 (46.57% Upside)
€33.07 (46.57% Upside)
Blogger Sentiment
Bullish
DE:ZA8 Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.45%
12-Months-Change
Fundamentals
Return on Equity
-37.79%
Trailing 12-Months
Asset Growth
12.38%
Trailing 12-Months
Company Description
Zymeworks
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
ZA8 Company Deck
ZA8 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.View all DE:ZA8 earnings summariesZA8 Stock 12 Month Forecast
Average Price Target
€33.07
▲(46.57% Upside)
Technical Analysis
Arcus Biosciences
―
Replimune Group
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Options Prices
Currently, No data available
---